title: Rilonacept in the management of cryopyrin-associated periodic syndromes (CAPS).
abstract: Cryopyrin-associated periodic syndromes (CAPS) are a subgroup of the hereditary periodic fever syndromes, which are rare autoinflammatory and inherited disorders, characterized by recurrent inflammation and varying degrees of severity. CAPS are thought to be driven by excessive production of interleukin-1β (IL-1β), through over-activation of the inflammasome by gain of function mutations in the gene encoding cryopyrin (NLRP3). This conclusion is supported by the remarkable efficacy of IL-1β blockade in these conditions. Rilonacept (Arcalyst(TM); Regeneron) is the first us Food and Drug Administration-approved treatment for familial cold autoinflammatory syndrome and Muckle-Wells syndrome and the first in a new line of drugs designed for longer-acting IL-1 blockade. Rilonacept has been associated with a decrease in disease activity, high-sensitivity C-reactive protein (hsCRP) and serum amyloid A (SAA) in the treatment of CAPS. The clinical safety and efficacy of rilonacept in CAPS and non-CAPS populations will be summarized in this review. Rilonacept is also beneficial for patients who tolerate injections poorly, due to an extended half-life over the unapproved CAPS treatment, anakinra, requiring weekly rather than daily self-administration. Other autoinflammatory disorders may also benefit from rilonacept treatment, with clinical trials in progress for systemic onset juvenile idiopathic arthritis, gout and familial mediterranean fever.
authors.affiliation: NIHR-Leeds Musculoskeletal Biomedical Research Unit (NIHR-LMBRU), Leeds Institute of Molecular Medicine (LIMM), St. James's University Hospital, Leeds, UK.
authors.forename: Justin
authors.initials: J
authors.lastname: Gillespie
authors.forename: Rebeccah
authors.initials: R
authors.lastname: Mathews
authors.forename: Michael F
authors.initials: MF
authors.lastname: McDermott
references.citation: Rheumatology (Oxford). 2010 Jan;49(1):5-14
references.pmid: 19808695
references.citation: Arthritis Rheum. 2008 Aug;58(8):2443-52
references.pmid: 18668535
references.citation: Expert Opin Biol Ther. 2009 Apr;9(4):519-31
references.pmid: 19344287
references.citation: J Exp Med. 2005 May 2;201(9):1479-86
references.pmid: 15851489
references.citation: Curr Med Res Opin. 2008 Jun;24(6):1577-82
references.pmid: 18423104
references.citation: Arthritis Rheum. 2008 Aug;58(8):2432-42
references.pmid: 18668591
references.citation: Nat Clin Pract Rheumatol. 2008 Sep;4(9):481-9
references.pmid: 18665151
references.citation: Nat Genet. 2001 Nov;29(3):301-5
references.pmid: 11687797
references.citation: Arthritis Rheum. 2005 Mar;52(3):818-25
references.pmid: 15751095
references.citation: J Autoimmun. 2005;25 Suppl:26-8
references.pmid: 16260118
references.citation: Nature. 2008 Mar 6;452(7183):103-7
references.pmid: 18288107
references.citation: J Allergy Clin Immunol. 2001 Oct;108(4):615-20
references.pmid: 11590390
references.citation: Diabetes Metab Res Rev. 2009 May;25(4):321-4
references.pmid: 19405081
references.citation: Arthritis Rheum. 2004 Dec;50(12):4045-50
references.pmid: 15593220
references.citation: Immunol Rev. 2008 Jun;223:20-38
references.pmid: 18613828
references.citation: Arthritis Rheum. 2002 Dec;46(12):3340-8
references.pmid: 12483741
references.citation: Nat Rev Rheumatol. 2009 Oct;5(10):529-30
references.pmid: 19798026
references.citation: Annu Rev Immunol. 2009;27:229-65
references.pmid: 19302040
references.citation: Arthritis Rheum. 2002 Sep;46(9):2445-52
references.pmid: 12355493
references.citation: J Orthop Res. 2003 Mar;21(2):256-64
references.pmid: 12568957
references.citation: Int J Rheum Dis. 2009 Apr;12(1):14-9
references.pmid: 20374311
references.citation: J Rheumatol. 2008 Feb;35(2):357-8
references.pmid: 18260167
references.citation: J Cutan Med Surg. 2008 Jan-Feb;12(1):8-16
references.pmid: 18258152
references.citation: Curr Allergy Asthma Rep. 2007 Sep;7(5):323-30
references.pmid: 17697637
references.citation: Cardiovasc Hematol Agents Med Chem. 2008 Apr;6(2):150-8
references.pmid: 18473780
references.citation: N Engl J Med. 2009 Jun 4;360(23):2416-25
references.pmid: 19494217
references.citation: Ann Rheum Dis. 2009 Oct;68(10):1613-7
references.pmid: 19635719
references.citation: N Engl J Med. 2003 Jun 19;348(25):2583-4
references.pmid: 12815153
references.citation: Carcinogenesis. 2009 Apr;30(4):698-705
references.pmid: 19233959
references.citation: Nat Med. 2003 Jan;9(1):47-52
references.pmid: 12483208
references.citation: P T. 2009 Mar;34(3):138-41
references.pmid: 19561849
references.citation: Curr Opin Immunol. 2007 Dec;19(6):615-22
references.pmid: 17977705
references.citation: Nat Clin Pract Rheumatol. 2008 Jan;4(1):34-42
references.pmid: 18172447
references.citation: Bull NYU Hosp Jt Dis. 2007;65(3):205-11
references.pmid: 17922671
references.citation: Lancet. 2004 Nov 13-19;364(9447):1779-85
references.pmid: 15541451
references.citation: Am J Kidney Dis. 2007 Mar;49(3):477-81
references.pmid: 17336710
references.citation: Scand J Rheumatol Suppl. 1987;66:57-68
references.pmid: 3482735
references.citation: Lab Invest. 2009 Apr;89(4):470-84
references.pmid: 19188913
references.citation: Annu Rev Immunol. 2009;27:519-50
references.pmid: 19302047
references.citation: Ann Rheum Dis. 2008 Mar;67(3):302-8
references.pmid: 17947302
references.citation: Joint Bone Spine. 2008 Jul;75(4):504-5
references.pmid: 18541452